Associated Data

Cervical cancer under 30

Conținutul

    Lancet Oncol ; 20 8 :Aug. This phase trial evaluated the safety and efficacy of the hafnium oxide HfO2 nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma.

    cervical cancer under 30

    Sarc is a phase randomised, multicentre, international trial. Patients had to have a WHO performance status of and a life expectancy of at least 6 months.

    Abstract Background The outcome of breast cancer treatment largely depends on the timing of detection.

    Randomisation was stratified by histological subtype myxoid liposarcoma vs others. This was an open-label study.

    cervical cancer under 30 wart removal home remedy apple cider vinegar

    The primary endpoint was the proportion of patients with a pathological complete response, assessed by a central pathology review board following European Organisation for Research and Treatment of Cancer guidelines in the intention-to-treat population full analysis set.

    Safety analyses were done in all patients who received at least one puncture and injection of NBTXR3 or at least one dose of radiotherapy.

    This study is registered with ClinicalTrials. Two patients in the NBTXR3 group and one patient in the radiotherapy group were excluded from the efficacy analysis because they were subsequently discovered to be ineligible; thus, a total of cervical cancer under 30 were analysed for the primary endpoint in the intention-to-treat full analysis set 87 in the NBTXR3 group cervical cancer under 30 89 in the radiotherapy alone group.

    No treatment-related deaths occurred.

    cervical cancer under 30 antibiotique contre papillomavirus